ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International PLC (KNSA)

55,11
0,90
(1,66%)
Geschlossen 20 Juni 10:00PM
55,11
-0,09
(-0,16%)
Nach Börsenschluss: 1:55AM

Kiniksa Pharmaceuticals International PLC (KNSA) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
55,11
( 1,66% )
Gebot
52,00
Fragen
56,44
Volumen
781.016
54,33 Tagesbereich 55,99
26,27 52-Wochen-Bereich 59,87
Marktkapitalisierung
Handelsende
54,21
Handelsbeginn
55,00
Letzter Handelszeitpunkt
Finanzvolumen
US$ 43.018.253
VWAP
55,0799
Durchschnittliches Volumen (3 Mio.)
US$ 658.408
Ausgegebene Aktien
76.938.016
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
57,62
Gewinn pro Aktie (EPS)
0,91
Erlöse (LTM)
754,05M
Nettogewinn (LTM)
73,06M

Über Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
London, United Kingdom
Gegründet
2026
Kiniksa Pharmaceuticals International PLC is listed in the Healthcare sector of the NASDAQ with ticker KNSA. The last closing price for Kiniksa Pharmaceuticals was US$54,21. Over the last year, Kiniksa Pharmaceuticals shares have traded in a share price range of US$ 26,27 to US$ 59,87.

Kiniksa Pharmaceuticals currently has 76.938.016 shares in issue. The market capitalisation of Kiniksa Pharmaceuticals is US$4,24 billion. Kiniksa Pharmaceuticals has a price to earnings ratio (PE ratio) of 57.62.

KNSA Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
15.9112.01219512249.255.248.70552654452.55017727CS
41.522.8363500653153.5955.3346.100454178350.59441858CS
129.3620.459016393445.7559.8741.4966053950.26144004CS
2613.733.083796184541.4159.8737.0263299946.96073471CS
5227.1697.173524150327.9559.8726.2759911640.68545832CS
15639.57254.63320463315.5459.8713.5550853628.60669688CS
26040.57279.02338376914.5459.877.3645524823.26812541CS

KNSA - Frequently Asked Questions (FAQ)

What is the current Kiniksa Pharmaceuticals International PLC share price?
The current share price of Kiniksa Pharmaceuticals International PLC is US$ 55,11
How many Kiniksa Pharmaceuticals International PLC shares are in issue?
Kiniksa Pharmaceuticals International PLC has 76.938.016 shares in issue
What is the market cap of Kiniksa Pharmaceuticals International PLC?
The market capitalisation of Kiniksa Pharmaceuticals International PLC is USD 4,24B
What is the 1 year trading range for Kiniksa Pharmaceuticals International PLC share price?
Kiniksa Pharmaceuticals International PLC has traded in the range of US$ 26,27 to US$ 59,87 during the past year
What is the PE ratio of Kiniksa Pharmaceuticals International PLC?
The price to earnings ratio of Kiniksa Pharmaceuticals International PLC is 57,62
What is the cash to sales ratio of Kiniksa Pharmaceuticals International PLC?
The cash to sales ratio of Kiniksa Pharmaceuticals International PLC is 5,34
What is the registered address of Kiniksa Pharmaceuticals International PLC?
The registered address for Kiniksa Pharmaceuticals International PLC is 105 Piccadilly, London, Greater London, W1J 7NJ
What is the Kiniksa Pharmaceuticals International PLC website address?
The website address for Kiniksa Pharmaceuticals International PLC is www.kiniksa.com
Which industry sector does Kiniksa Pharmaceuticals International PLC operate in?
Kiniksa Pharmaceuticals International PLC operates in the Biotechnology & Life Sciences sector

KNSA Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen